A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Carcinoma, Transitional Cell Urinary Bladder Neoplasms Urologic Neoplasms Renal Pelvis Neoplasms Urothelial Cancer Ureteral Neoplasms Urethral Neoplasms ASG-22ME ASG-22CE Antibody-drug conjugate Antineoplastic agents CPI Enfortumab vedotin MIBC Locally advanced urothelial cancer Cisplatin Drug therapy Carboplatin Metastatic urothelial cancer Nectin-4 Gemcitabine Muscle invasive bladder cancer Checkpoint Inhibitors Pembrolizumab PD-1 inhibitor Neoplasms Pelvic Neoplasms enfortumab vedotin (EV) EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L
Lead Scientist at UCSF
- Terence Friedlander
I am a clinical and translational medical oncologist with a focused on urologic cancers, specifically cancers of the bladder, prostate, and kidney. I am also the Chief of the ZSFG Division of Hematology and Oncology. My research is focused on understanding the basic biology of urologic and other malignancies and in developing novel therapeutic ways to treat disease.
- accepting new patients
- Start Date
- Completion Date
- Astellas Pharma Global Development, Inc.
- Phase 1/2
- Study Type
- Last Updated